

Exponential Technologies Fund Commentary

December 31, 2024

AT A GLANCE

Manager: Funny Kuruvilla, MD, PhD

Fund Objective: Seeks to provide long-term capital appreciation.

About the Fund: A concentrated mutual fund representing our thesis regarding long-term capital appreciation in technology which can include information technology, e-commerce discretionary, internet media and services, healthcare technology, healthcare devices, or transaction and payment processing services industries (≥80%). The fund has a non-diversified approach in which ≥5% holdings cumulatively can be ≥25% of the fund. May invest in illiquid securities (≤15%).

Benchmark: Bloomberg US 2500 Technology Total Return Index

Morningstar Category: US Fund Technology

Lipper Category: Technology

Net Assets: \$112 million

Inception Date: June 30, 2020

GLOSSARY

Moat: Competitive strategy that helps protect a company's market position from competitors

Eventide Asset Management, LLC

One International Place, Suite 4210
Boston, MA 02110
877-771-EVEN (3836)

WWW.EVENTIDEFUNDS.COM

Class I: ETIEX | Class A: ETAEX | Class C: ETCEX | Class N: ETNEX

Review

The Eventide Exponential Technologies Fund (Class I) posted a total return of 10.09% for the fourth quarter of 2024, outperforming the Bloomberg US 2500 Technology Total Return Index of 8.25%. The Fund (Class I) posted a total return of 2.52% for the 12 months ending 12/31/2024 compared to the Bloomberg US 2500 Technology Total Return Index of 18.48%.

Contributors

Top Five Contributors¹ (%)

Q4 2024

Company	Ticker	Sub-Industry	Average Weight	Contribution to Return	Total Return ²
Xometry Inc	XMTR	Trading Companies & Distribution	5.47	5.03	132.23
Global-e Online Ltd	GLBE	Broadline Retail	3.11	1.18	41.86
Toast Inc	TOST	Transaction & Payment Processing	3.59	0.94	28.75
Arteris Inc	AIP	Systems Software	2.29	0.72	31.99
Ciena Corp	CIEN	Communications Equipment	2.25	0.61	37.70

In the fourth quarter of 2024, the largest positive contributors to performance were: Xometry Inc, Global-e Online Ltd, Toast Inc, Arteris Inc, and Ciena Corp. Xometry Inc is an AI-enabled marketplace for on-demand manufacturing. Its distributed manufacturing network is a perceived tariff and onshoring beneficiary. The company achieved roughly break-even profitability as marketplace growth outpaced expectations. Global-e Online Ltd, which develops end-to-end cross-border platforms for eBusiness, accelerated on new large merchant adds despite macro softness in consumer discretionary categories. Toast Inc, which develops cloud software to equip restaurants to thrive, saw its SaaS platform continue to scale faster than expected on new location adds and pricing adjustments. Arteris Inc, a provider of network-on-chip semiconductor intellectual property, benefited from strong organic growth and improving profitability metrics. Ciena Corp, which provides communications network platforms, software, and professional services, benefited from strong demand from its datacenter customers.

Detractors

Top Five Detractors¹ (%)

Q4 2024

Company	Ticker	Sub-Industry	Average Weight	Contribution to Return	Total Return ²
Monday.com Ltd	MNDY	Systems Software	2.95	-0.29	-15.24
ICF International Inc	ICFI	Research & Consulting Services	1.37	-0.46	-28.45
Monolithic Power Systems Inc	MPWR	Semiconductors	1.68	-0.82	-35.86
Evolent Health Inc	EVH	Health Care Technology	1.00	-1.01	-60.22
TransMedics Group Inc	TMDX	Health Care Equipment	0.98	-1.17	-57.10

In the fourth quarter of 2024, the largest negative detractors to performance were: Monday.com Ltd, ICF International Inc, Monolithic Power Systems Inc, Evolent Health Inc, and TransMedics Group Inc. Monday.com Ltd, a platform for streamlining team collaboration, project management, and productivity, saw its upside in the quarter below expectations; management made negative comments about Europe intra-quarter during a conference presentation. ICF International Inc, which delivers consulting, technology, and policy services to drive impactful societal solutions, underperformed after Trump's election and DOGE speculation due to its exposure to government spending. Monolithic Power Systems Inc,

Performance is historical and does not guarantee future results.

Portfolio Team Outlook

It was an eventful quarter to finish a year characterized by a dynamic macroeconomic and geopolitical environment. Trump’s decisive victory led to a broad market rally as the overhang of election risk uncertainty cleared. Technology was no exception, with most sub-industries moving decidedly higher to finish the year. While the market was happy to move past the election, much uncertainty remains around the implications of Trump’s first days in office.

Despite this environment, our Strategy’s investments outperformed their benchmark on a relative basis in the fourth quarter. Outperformance in the quarter was driven primarily by stock selection rather than industry- or factor-related effects. Following some quarters of underperformance, it was reassuring to see outperformance in the quarter driven by a focused group of high-conviction ideas.

While one quarter does not make a trend, we are encouraged to see early progress from the improvements to portfolio construction

and risk management mentioned in last quarter’s commentary. To reiterate, we believe that a more proactive approach to portfolio-level risk will allow our team to focus even more on bottoms-up, fundamental stock picking in those parts of the market where we seek to bring the most differentiation.

Looking forward, we continue to seek attractive opportunities to invest in high-quality growth companies that are leaders in their industries. While certain areas of technological innovation remain out of favor, we continue to focus on high-quality companies that enjoy wide moats because of their differentiated ability to meet important human needs. Potential risks to this approach include market or stock movements from forces outside of a company’s control such as the trajectory of monetary policy, slower than expected cyclical recoveries, adverse trade or geopolitical developments, and the ever-present risk of disruption from even



Finny Kuruvilla, MD, PhD
Co-Chief Investment Officer,
Senior Portfolio Manager

newer emerging technologies. However, we believe our disciplined investment process and focus on companies with sustainable competitive advantages based on value creation for all stakeholders will continue to serve our investors well over the long term.

As a team, we remain grounded in the view that exponential growth can be unlocked over market cycles for investors who have the risk appetite and patience to invest in those areas where we see real technological innovation in pursuit of human flourishing. We are grateful to our investors for their continued trust and partnership in our shared pursuit of this goal.

provider of power management solutions, reported worse than expected data center revenues. Evolent Health Inc, provider of value-based care initiatives in specialty and primary care, missed 3Q24 estimates and guided down 4Q24 expectations as cost trends remained high alongside unexpected, temporary prior period claims. TransMedics Group Inc, which provides therapy for end-stage organ failure, delivered 3Q24 results below consensus expectations resulting from a weak market quarter and logistics bottlenecks.

Trailing Returns³ (%)

31 Dec 2024

	YTD	3-mos	1-year	3-year ⁴	5-year	10-year	Since Inception ⁴	Inception Date
<i>Eventide Exponential Technologies Fund</i>								
Class I	2.52	10.09	2.52	-9.37	—	—	7.09	06/30/2020
Class A without load	2.23	9.93	2.23	-9.59	—	—	6.84	06/30/2020
Class A with 5.75% load ⁵	-3.63	3.59	-3.63	-11.36	—	—	5.45	06/30/2020
Class C ⁵	1.42	9.74	1.42	-10.28	—	—	6.05	06/30/2020
Class N	2.31	10.02	2.31	-9.57	—	—	6.86	06/30/2020
<i>Benchmark</i>								
Bloomberg US 2500 Technology Total Return Index ⁶	18.48	8.25	18.48	1.40	—	—	11.06	06/30/2020

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).

Eventide Exponential Technologies Fund expenses: Class I, Gross Expenses 1.49%, Net Expenses 1.43%; Class A, Gross Expenses 1.74%, Net Expenses 1.68%; Class C, Gross Expenses 2.49%, Net Expenses 2.43%; Class N, Gross Expenses 1.69%, Net Expenses 1.63%. The adviser has contractually agreed to waive fees and/or

reimburse expenses of the Fund through 10/31/2025. The agreement may be terminated by the Fund's Board of Trustees only on 60 days' written notice.

1. Source: Bloomberg PORT Attribution Report. Allocation percentages are subject to change at any time, and should not be considered investment advice.
2. The total return percentage listed is impacted by the Fund's transactions and transacted price levels of the holding during the quarter.
3. The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.
4. Performance figures for periods greater than 1 year are annualized. Annualized since inception figures use an inception date of 06/30/2020.
5. Class A and Class C are also subject to a maximum deferred sales charge of 1.00%. This and other expenses that apply to a continued investment in the Fund are described in the Fund's prospectus.
6. The Bloomberg US 2500 Technology Total Return Index is a float market-cap-weighted equity benchmark derived from membership of the Bloomberg US 2500 Index.

The opinions expressed herein are those of the Fund's portfolio management team as of 12/31/2024 and are subject to change. There is no guarantee that such views are correct or that the outlook opinions will come to pass. Specific companies mentioned are for performance attribution informational purposes only and should not be construed as buy or sell advice. Reliance upon the views expressed herein is at the sole discretion of the reader. The Adviser's judgment about the quality and intrinsic value of companies may prove to be incorrect. There is no guarantee that any investment will achieve its objectives, generate positive gains, or avoid losses.

Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results.

The Fund typically invests at least 80% of its net assets in companies that the Adviser believes are participating in and benefiting from technologies, innovations, technology themes, or technology trends which can include information technology, e-commerce discretionary, internet media and services, healthcare technology, healthcare devices, or transaction & payment processing services industries. The term "exponential" means the potential for accelerated advancements in underlying technologies that can positively impact capabilities and development cycles of a company's products and services. Not every company in the Fund's portfolio will experience exponential growth, and the Fund is not expected to deliver exponential returns. The Fund's ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund may experience higher volatility than the general market due to being concentrated in the technology industries. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Communications companies may underperform due to legislative or increased competition. Internet and Direct Marketing Retail companies may underperform due to legislative or increased government supervision. Healthcare Technology and Devices Companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the governments and regulatory authorities. Further, these companies are dependent on patent protection. The Fund has non-diversification risk as a high percentage of Fund assets may be invested in a limited number of companies. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks. The Fund has no history of operations prior to its inception date.

This information is for use with concurrent or prior delivery of a fund prospectus, which can be obtained at <https://www.eventidefunds.com/prospectus> or by calling 1-877-771-EVEN (3836). Investors should consider a Fund's investment objectives, risks, charges and expenses carefully before investing or sending money. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.